Skip to main content
SpringerLink
Log in

Vitamin D and Infectious Diseases

  • Chapter
  • First Online:
Extraskeletal Effects of Vitamin D

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

Since the eighteenth century, Vitamin D-rich adjuvant therapy has been used to treat conditions, which are nowadays considered infections. The infectious disease most frequently associated with Vitamin D is tuberculosis, and early scientific studies from the nineteenth century reported on the use of cod liver oil treatment, which remained an important part of tuberculosis treatment as late as in 1960. Vitamin D plays an independent modulatory role in the immune response toward infections, and infectious diseases have been associated with Vitamin D deficiency. Vitamin D deficiency is believed to be both a risk marker and a contributor to infectious diseases, and in recent years the association between infectious diseases, Vitamin D levels, and the use of Vitamin D adjuvant therapy have been widely examined for a number of infections. This chapter will explore these associations for tuberculosis, other respiratory tract infections, sepsis, HIV, and hepatitis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science. 1983;221(4616):1181–3.

    Article  CAS  PubMed  Google Scholar 

  2. Hayes CE, Nashold FE, Spach KM, Pedersen LB. The immunological functions of the vitamin D endocrine system. Cell Mol Biol (Noisy-Le-Grand). 2003;49(2):277–300.

    CAS  Google Scholar 

  3. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770–3.

    Article  CAS  PubMed  Google Scholar 

  4. Zasloff M. Fighting infections with vitamin D. Nat Med. 2006;12(4):388–90.

    Article  CAS  PubMed  Google Scholar 

  5. Korf H, Decallonne B, Mathieu C. Vitamin D for infections. Curr Opin Endocrinol Diabetes Obes. 2014;21(6):431–6.

    Article  CAS  PubMed  Google Scholar 

  6. Holtz F, Frohberg H. Role of the calcinosis factor (vitamin D, dihydrotachysterin) in therapy of tuberculosis. Beitr Klin Tuberk Spezif Tuberkuloseforsch. 1957;117(2):265–75.

    Article  CAS  PubMed  Google Scholar 

  7. Grad R. Cod and the consumptive: a brief history of cod-liver oil in the treatment of pulmonary tuberculosis. Pharm Hist. 2004;46(3):106–20.

    PubMed  Google Scholar 

  8. Bennett JH. Treatise on the oleum jecoris aselli. London: S. Highley; 1841.

    Google Scholar 

  9. Stillé A. Therapeutics and Materia Medica. Lond Monthly J. 1849:239.

    Google Scholar 

  10. Green M. Cod liver oil and tuberculosis. BMJ. 2011;343:d7505.

    Article  PubMed  Google Scholar 

  11. Wood GB. A treatise on the practice of medicine. 4th ed. Philadelphia: Lippincott, Grambo and Co.; 1855. p. 96–7.

    Google Scholar 

  12. Lyngbye J. Lyssagen. Niels Finsen og hans team på Finsensinstituttet. 1st ed. Copenhagen: Gyldendal; 2003.

    Google Scholar 

  13. David HL, Jones WD Jr, Newman CM. Ultraviolet light inactivation and photoreactivation in the mycobacteria. Infect Immun. 1971;4(3):318–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Riley RL, Knight M, Middlebrook G. Ultraviolet susceptibility of BCG and virulent tubercle bacilli. Am Rev Respir Dis. 1976;113(4):413–8.

    CAS  PubMed  Google Scholar 

  15. van der Lugt L, Rottier PB. Finsen therapy and vitamin D. Acta Derm Venereol. 1958;38(4):264–73.

    Google Scholar 

  16. Moller KI, Kongshoj B, Philipsen PA, Thomsen VO, Wulf HC. How Finsen’s light cured lupus vulgaris. Photodermatol Photoimmunol Photomed. 2005;21(3):118–24.

    Article  CAS  PubMed  Google Scholar 

  17. Charpy J. Aspects of vitamin and functional substance therapy in dermatology. Bull Med. 1950;64(24):555–9.

    CAS  PubMed  Google Scholar 

  18. Dowling GB, Prosser Thomas EW. Treatment of lupus vulgaris with calciferol. Lancet. 1946;1:919–22.

    Article  CAS  PubMed  Google Scholar 

  19. Riehl. Two years experience with vitamin D2 in the treatment of tuberculosis of the skin. Arch Klin Exp Dermatol. 1950;191:615–8.

    CAS  Google Scholar 

  20. Ruiter M, Groen HD. The effect of nonirradiated ergosterol in calciferol-treated tuberculosis cutis. Dermatologica. 1949;99(6):345–52.

    Article  CAS  PubMed  Google Scholar 

  21. Gutierrez PD, Fernandez MC. Vitamin D2 in cutaneous tuberculosis; (progress report). Acta Med Philipp. 1950;7(1):55–9.

    CAS  PubMed  Google Scholar 

  22. Thaler E. Treatment of tuberculosis of the skin with massive doses of vitamin D2. Med Monatsschr. 1950;4(6):452–4.

    CAS  PubMed  Google Scholar 

  23. Macrae DE. The use of calciferol in tuberculous conditions. Lancet. 1947;249(6439):135–7.

    Article  Google Scholar 

  24. Lomholt S. Calciferol therapy of lupus vulgaris. Acta Derm Venereol. 1950;30(4):329–33.

    CAS  PubMed  Google Scholar 

  25. Pogorzelski J, Miedzinski F. Six years of calciferol therapy in tuberculosis of the skin. Dermatologica. 1954;109(6):355–69.

    Article  CAS  PubMed  Google Scholar 

  26. Ellman P, Anderson K. Calciferol in tuberculosis peritonitis with disseminated tuberculosis. BMJ. 1948;1:394.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Wallis HR. Tuberculous mesenteric adenitis in children. Br Med J. 1955;1(4906):128–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Gerecke W. Vitamin D2 alone and in combination with TB 1/698 in the treatment of pulmonary tuberculosis. Z Tuberk. 1950;95(3–4):182–7.

    CAS  PubMed  Google Scholar 

  29. Brincourt J. Liquefying effect on suppurations of an oral dose of calciferol. Presse Med. 1969;77(13):467–70.

    CAS  PubMed  Google Scholar 

  30. Ghosh PK. Vitamin D2 in tuberculosis. J Indian Med Assoc. 1957;29(3):90–3.

    CAS  PubMed  Google Scholar 

  31. Trautwein H, Stein E. Vitamin D2 and pulmonary tuberculosis; effects and therapeutic results. Beitr Klin Tuberk Spezif Tuberkuloseforsch. 1952;107(4):295–313.

    Article  CAS  PubMed  Google Scholar 

  32. Gertler W. The question of late injuries in long lasting vitamin D treatment of cutaneous tuberculosis. Z Tuberk. 1953;103(1–3):26–50.

    CAS  PubMed  Google Scholar 

  33. Kalkoff KW. Chemotherapy and vitamin D therapy of skin tuberculosis. Ergeb Gesamten Tuberkuloseforsch. 1956;13:331–70.

    CAS  PubMed  Google Scholar 

  34. Winterberg H. Vigantol therapy in early tuberculous infections of the lungs, and in exsudative pulmonary tuberculosis. Z Tuberk. 1950;95(3–4):146–50.

    CAS  PubMed  Google Scholar 

  35. Marcussen PV. Treatment of lupus vulgaris with calciferol alone; results after five years of observation. Dan Med Bull. 1955;2(5):129–36.

    CAS  PubMed  Google Scholar 

  36. Seeber F. The use of vitamin D2 in the treatment of pulmonary tuberculosis. Z Tuberk. 1950;95(3–4):151–5.

    CAS  PubMed  Google Scholar 

  37. Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest. 2006;116(8):2062–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr. 1999;69(5):842–56.

    Article  CAS  PubMed  Google Scholar 

  39. Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr. 2007;85(1):6–18.

    Article  CAS  PubMed  Google Scholar 

  40. Fruhwald R. Changes in the blood analysis in vitamin D2 treatment of cutaneous tuberculosis. Dtsch Gesundheitsw. 1953;8(3):67–9.

    CAS  PubMed  Google Scholar 

  41. Sonne LM. Calciferol in dermatology. Ugeskr Laeger. 1952;114(4):109–13.

    CAS  PubMed  Google Scholar 

  42. Dowling GB. The present status of vitamin D2 in the treatment of lupus vulgaris. Dermatologica. 1957;115(4):491–5.

    Article  CAS  PubMed  Google Scholar 

  43. Fielding J, Maloney JJ. Calciferol, streptomycin, and para-aminosalicylic acid in pulmonary tuberculosis. Lancet. 1951;2(14):614–7.

    Article  CAS  PubMed  Google Scholar 

  44. Jongmans LJ, Hopmans PJ, Kars HJ, Michgelsen H. Danger of reactivating tuberculous processes in the lungs with the administration of massive doses of vitamin D2. Ned Tijdschr Geneeskd. 1950;94(34):2470–3.

    CAS  PubMed  Google Scholar 

  45. Grassi A. Modern therapy of cutaneous tuberculosis. Minerva Med. 1957;48(51):2269–73.

    CAS  PubMed  Google Scholar 

  46. Martineau AR, Wilkinson RJ, Wilkinson KA, Newton SM, Kampmann B, Hall BM, et al. A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med. 2007;176(2):208–13.

    Article  CAS  PubMed  Google Scholar 

  47. Coussens AK, Wilkinson RJ, Hanifa Y, Nikolayevskyy V, Elkington PT, Islam K, Timms PM, Venton TR, Bothamley GH, Packe GE, Darmalingam M, Davidson RN, Milburn HJ, Baker LV, Barker RD, Mein CA, Bhaw-Rosun L, Nuamah R, Young DB, Drobniewski FA, Griffiths CJ, Martineau AR. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci U S A. 2012;109(38):15449–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Wilkinson RJ, Llewelyn M, Toossi Z, Patel P, Pasvol G, Lalvani A, et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet. 2000;355(9204):618–21.

    Article  CAS  PubMed  Google Scholar 

  49. Ustianowski A, Shaffer R, Collin S, Wilkinson RJ, Davidson RN. Prevalence and associations of vitamin D deficiency in foreign-born persons with tuberculosis in London. J Infect. 2005;50(5):432–7.

    Article  CAS  PubMed  Google Scholar 

  50. Wejse C, Olesen R, Rabna P, Kaestel P, Gustafson P, Aaby P, et al. Serum 25-hydroxy-vitamin D in a West African population of tuberculosis patients and un-matched healthy controls. Am J Clin Nutr. 2007;86(5):1376–83.

    Article  CAS  PubMed  Google Scholar 

  51. Zeng J, Wu G, Yang W, Gu X, Liang W, Yao Y, Song Y. A serum vitamin D level <25nmol/l pose high tuberculosis risk: a meta-analysis. PLoS One. 2015;10(5):e0126014.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Stead WW, Senner JW, Reddick WT, Lofgren JP. Racial differences in susceptibility to infection by Mycobacterium tuberculosis. N Engl J Med. 1990;322(7):422–7.

    Article  CAS  PubMed  Google Scholar 

  53. Harris SS. Vitamin D and African Americans. J Nutr. 2006;136(4):1126–9.

    Article  CAS  PubMed  Google Scholar 

  54. Bellamy R, Ruwende C, Corrah T, McAdam KP, Thursz M, Whittle HC, Hill AV. Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J Infect Dis. 1999;179(3):721–4.

    Article  CAS  PubMed  Google Scholar 

  55. Bornman L, Campbell SJ, Fielding K, Bah B, Sillah J, Gustafson P, et al. Vitamin D receptor polymorphisms and susceptibility to tuberculosis in West Africa: a case-control and family study. J Infect Dis. 2004;190(9):1631–41.

    Article  CAS  PubMed  Google Scholar 

  56. Olesen R, Wejse C, Velez DR, Bisseye C, Sodemann M, Aaby P, et al. DC-SIGN (CD209), pentraxin 3 and vitamin D receptor gene variants associate with pulmonary tuberculosis risk in West Africans. Genes Immun. 2007;8(6):456–67.

    Article  CAS  PubMed  Google Scholar 

  57. Roth DE, Soto G, Arenas F, Bautista CT, Ortiz J, Rodriguez R, et al. Association between vitamin D receptor gene polymorphisms and response to treatment of pulmonary tuberculosis. J Infect Dis. 2004;190(5):920–7.

    Article  CAS  PubMed  Google Scholar 

  58. Soborg C, Andersen AB, Range N, Malenganisho W, Friis H, Magnussen P, et al. Influence of candidate susceptibility genes on tuberculosis in a high endemic region. Mol Immunol. 2007;44(9):2213–20.

    Article  CAS  PubMed  Google Scholar 

  59. Gao L, Tao Y, Zhang L, Jin Q. Vitamin D receptor genetic polymorphisms and tuberculosis: updated systematic review and meta-analysis. Int J Tuberc Lung Dis. 2010;14(1):15–23.

    CAS  PubMed  Google Scholar 

  60. Wejse C, Gomes VF, Rabna P, Gustafson P, Aaby P, Lisse I, Andersen PL, Glerup H, Sodemann M. Vitamin D as supplementary treatment for tuberculosis—a randomised double-blind placebo-controlled trial. Am J Respir Crit Care Med. 2009;179:843–50.

    Article  CAS  PubMed  Google Scholar 

  61. Zittermann A, Pilz S, Hoffmann H, März W. Vitamin D and airway infections: a European perspective. Eur J Med Res. 2016;21:14.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  62. Ganmaa D, Giovannucci E, Bloom BR, Fawzi W, Burr W, Batbaatar D, et al. Vitamin D, tuberculin skin test conversion, and latent tuberculosis in Mongolian school-age children: a randomized, double-blind, placebocontrolled feasibility trial. Am J Clin Nutr. 2012;96:391.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Lawn SD, Macallan DC. Hypercalcemia: a manifestation of immune reconstitution complicating tuberculosis in an HIV-infected person. Clin Infect Dis. 2004;38(1):154–5.

    Article  PubMed  Google Scholar 

  64. Roussos A, Lagogianni I, Gonis A, Ilias I, Kazi D, Patsopoulos D, et al. Hypercalcaemia in Greek patients with tuberculosis before the initiation of anti-tuberculosis treatment. Respir Med. 2001;95(3):187–90.

    Article  CAS  PubMed  Google Scholar 

  65. Chan TY. Symptomatic hypercalcaemia is rare in tuberculous patients in Hong Kong. Ann Trop Med Parasitol. 1996;90(6):663–4.

    Article  CAS  PubMed  Google Scholar 

  66. Tan TT, Lee BC, Khalid BA. Low incidence of hypercalcaemia in tuberculosis in Malaysia. J Trop Med Hyg. 1993;96(6):349–51.

    CAS  PubMed  Google Scholar 

  67. Kelestimur F, Guven M, Ozesmi M, Pasaoglu H. Does tuberculosis really cause hypercalcemia? J Endocrinol Invest. 1996;19(10):678–81.

    Article  CAS  PubMed  Google Scholar 

  68. Fuss M, Karmali R, Pepersack T, Bergans A, Dierckx P, Prigogine T, et al. Are tuberculous patients at a great risk from hypercalcemia? Q J Med. 1988;69(259):869–78.

    CAS  PubMed  Google Scholar 

  69. Salimpour R. Rickets in Tehran. Arch Dis Child. 1975;50:63–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Lubani MM, Al-Shab TS, Al-Saleh QA, et al. Vitamin-D-deficiency rickets in Kuwait: the prevalence of a preventable disease. Ann Trop Paediatr. 1989;3:134–9..

    Article  CAS  PubMed  Google Scholar 

  71. Lawson DEM, Cole TJ, Salem SI, et al. Aetiology of rickets in Egyptian children. Hum Nutr Clin Nutr. 1987;41:199–208.

    CAS  PubMed  Google Scholar 

  72. Muhe L, Lulseged S, Mason KE, Simoes EA. Case-control study of the role of nutritional rickets in the risk of developing pneumonia in Ethiopian children. Lancet. 1997;349(9068):1801–4.

    Article  CAS  PubMed  Google Scholar 

  73. Jat KR. Vitamin D deficiency and lower respiratory tract infections in children: a systematic review and meta-analysis of observational studies. Trop Dr. 2017;47(1):77–84.

    Google Scholar 

  74. Ginde AA, Mansbach JM, Camargo CA Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2009;169(4):384–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Berry DJ, et al. Vitamin D status has a linear association with seasonal infections and lung function in British adults. Br J Nutr. 2011;106:1433–40.

    Article  CAS  PubMed  Google Scholar 

  76. Laaksi I, Ruohola JP, Tuohimaa P, Auvinen A, Haataja R, Pihlajamäki H, et al. An association of serum vitamin D concentrations <40 nmol/L with acute respiratory tract infection in young Finnish men. Am J Clin Nutr. 2007;86:714.

    Article  CAS  PubMed  Google Scholar 

  77. Jolliffe DA, Griffiths CJ, Martineau AR. Vitamin D in the prevention of acute respiratory infection: systematic review of clinical studies. J Steroid Biochem Mol Biol. 2013;136:321–9.

    Article  CAS  PubMed  Google Scholar 

  78. Bryson KJ, Nash AA, Norval M. Does vitamin D protect against respiratory viral infections? Epidemiol Infect. 2014;142(9):1789–801.

    Article  CAS  PubMed  Google Scholar 

  79. Manaseki-Holland S, et al. Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: a randomised controlled superiority trial. Lancet. 2012;379:1419–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Youssef D, Bailey B, El-Abbassi A, Vannoy M, Manning T, Moorman JP, et al. Healthcare costs of methicillin resistant Staphylococcus aureus and Pseudomonas aeruginosa infections in veterans: role of vitamin D deficiency. Eur J Clin Microbiol Infect Dis. 2012;31(3):281–6.

    Article  CAS  PubMed  Google Scholar 

  81. Thomason J, Rentsch C, Stenehjem EA, Hidron AI, Rimland D. Association between vitamin D deficiency and methicillin-resistant Staphylococcus aureus infection. Infection. 2015;43(6):715–22.

    Article  CAS  PubMed  Google Scholar 

  82. Matheson EM, Mainous AG III, Hueston WJ, Diaz VA, Everett CJ. Vitamin D and methicillin-resistant Staphylococcus aureus nasal carriage. Scand J Infect Dis. 2010;42(6–7):455–60.

    Article  CAS  PubMed  Google Scholar 

  83. Watkins RR, Yamshchikov AV, Lemonovich TL, Salata RA. The role of vitamin D deficiency in sepsis and potential therapeutic implications. J Infect. 2011;63(5):321–6.

    Article  PubMed  Google Scholar 

  84. Jeng L, Yamshchikov AV, Judd SE, Blumberg HM, Martin GS, Ziegler TR, et al. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J Transl Med. 2009;7:28.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  85. Lange N, Litonjua AA, Gibbons FK, Giovannucci E, Christopher KB. Pre-hospital vitamin D concentration, mortality, and bloodstream infection in a hospitalized patient population. Am J Med. 2013;126(7):640.e19–27.

    Article  CAS  Google Scholar 

  86. de Haan K, Groeneveld AB, de Geus HR, Egal M, Struijs A. Vitamin D deficiency as a risk factor for infection, sepsis and mortality in the critically ill: systematic review and meta-analysis. Crit Care. 2014;18(6):660.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Upala S, Sanguankeo A, Permpalung N. Significant association between vitamin D deficiency and sepsis: a systematic review and meta-analysis. BMC Anesthesiol. 2015;15:84.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  88. Leaf DE, Raed A, Donnino MW, et al. Randomized controlled trial of calcitriol in severe sepsis. Am J Respir Crit Care Med. 2014;190:533–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Mata-Granados JM, Vargas-Vasserot J, Ferreiro-Vera C, et al. Evaluation of vitamin D endocrine system (VDES) status and response to treatment of patients in intensive care units (ICUs) using an on-line SPE-LC-MS/MS method. J Steroid Biochem Mol Biol. 2010;121:452–5.

    Article  CAS  PubMed  Google Scholar 

  90. Amrein K, Schnedl C, Holl A, et al. Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial. JAMA. 2014;312:1520–30.

    Article  PubMed  CAS  Google Scholar 

  91. Connor RI, Rigby WFC. 1a,25-Dihydroxyvitamin D3 inhibits productive infection of human monocytes by HIV-1. Biochem Biophys Res Commun. 1991;176(2):852–9.

    Article  CAS  PubMed  Google Scholar 

  92. Kizaki M, Ikeda Y, Simon KJ, Nanjo M, Koeffler HP. Effect of 1,25-dihydroxyvitamin D3 and its analogs on human immunodeficiency virus infection in monocytes/macrophages. Leukemia. 1993;7(10):1525–30.

    CAS  PubMed  Google Scholar 

  93. Khoo AL, Chai L, Koenen H, Joosten I, Netea M, Van Der Ven A. Translating the role of vitamin D 3 in infectious diseases. Crit Rev Microbiol. 2012;38(2):122–35.

    Article  CAS  PubMed  Google Scholar 

  94. Villamor E. A potential role for vitamin D on HIV infection? Nutr Rev. 2006;64(5):226–33.

    Article  PubMed  Google Scholar 

  95. Bergman P, Walter-Jallow L, Broliden K, Agerberth B, Söderlund J. The antimicrobial peptide LL-37 inhibits HIV-1 replication. Curr HIV Res. 2007;5(4):410–5.

    Article  CAS  PubMed  Google Scholar 

  96. Lake JE, Adams JS. Vitamin D in HIV-infected patients. Curr HIV/AIDS Rep. 2011;8(3):133–41.

    Article  PubMed  Google Scholar 

  97. Griffin AT, Arnold FW. Review of metabolic, immunologic, and virologic consequences of suboptimal vitamin D levels in HIV infection. AIDS Patient Care STDs. 2012;26(9):516–25.

    Article  PubMed  Google Scholar 

  98. Pinzone MR, Di Rosa M, Malaguarnera M, Madeddu G, Focà E, Ceccarelli G, et al. Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic. Eur Rev Med Pharmacol Sci. 2013;17(9):1218–32.

    CAS  PubMed  Google Scholar 

  99. Mansueto P, Seidita A, Vitale G, Gangemi S, Iaria C, Cascio A. Vitamin D deficiency in HIV infection: not only a bone disorder. BioMed Res Int. 2015;2015:735615.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  100. Havers F, Smeaton L, Gupte N, Detrick B, Bollinger RC, Hakim J, et al. 25-hydroxyvitamin D insufficiency and deficiency is associated with HIV disease progression and virological failure post-antiretroviral therapy initiation in diverse multinational settings. J Infect Dis. 2014;210(2):244–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Shepherd L, Souberbielle JC, Bastard JP, Fellahi S, Capeau J, Reekie J, et al. Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons. J Infect Dis. 2014;210(2):234–43.

    Article  CAS  PubMed  Google Scholar 

  102. Mehta S, Giovannucci E, Mugusi FM, Spiegelman D, Aboud S, Hertzmark E, et al. Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One. 2010;5(1):e8770.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  103. Terrier B, Carrat F, Geri G, Pol S, Piroth L, Halfon P, et al. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. J Hepatol. 2011;55(4):756–61.

    Article  CAS  PubMed  Google Scholar 

  104. Haug C, Müller F, Aukrust P, Frøland SS. Subnormal serum concentration of 1, 25-vitamin d in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. J Infect Dis. 1994;169(4):889–93.

    Article  CAS  PubMed  Google Scholar 

  105. Dao CN, Patel P, Overton ET, Rhame F, Pals SL, Johnson C, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the us general population. Clin Infect Dis. 2011;52(3):396–405.

    Article  CAS  PubMed  Google Scholar 

  106. Brown TT, McComsey GA. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther. 2010;15(3):425–9.

    Article  CAS  PubMed  Google Scholar 

  107. Mueller NJ, Fux CA, Ledergerber B, Elzi L, Schmid P, Dang T, et al. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS. 2010;24(8):1127–34.

    Article  CAS  PubMed  Google Scholar 

  108. Welz T, Childs K, Ibrahim F, Poulton M, Taylor CB, Moniz CF, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS. 2010;24(12):1923–8.

    Article  CAS  PubMed  Google Scholar 

  109. Fox J, Peters B, Prakash M, Arribas J, Hill A, Moecklinghoff C. Improvement in vitamin D deficiency following antiretroviral regime change: results from the MONET trial. AIDS Res Hum Retrovir. 2011;27(1):29–34.

    Article  CAS  PubMed  Google Scholar 

  110. Conesa-Botella A, Florence E, Lynen L, Colebunders R, Menten J, Moreno-Reyes R. Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen. AIDS Res Ther. 2010;7:40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003;17(4):513–20.

    Article  CAS  PubMed  Google Scholar 

  112. Cervero M, Agud JL, Torres R, García-Lacalle C, Alcázar V, Jusdado JJ, et al. Higher vitamin D levels in HIV-infected out-patients on treatment with boosted protease inhibitor monotherapy. HIV Med. 2013;14(9):556–62.

    Article  CAS  PubMed  Google Scholar 

  113. Lang PO, Samaras N, Samaras D, Aspinall R. How important is vitamin D in preventing infections? Osteoporos Int. 2013;24(5):1537–53.

    Article  CAS  PubMed  Google Scholar 

  114. Kakalia S, Sochett EB, Stephens D, Assor E, Read SE, Bitnun A. Vitamin D supplementation and CD4 count in children infected with human immunodeficiency virus. J Pediatr. 2011;159(6):951–7.

    Article  CAS  PubMed  Google Scholar 

  115. Arpadi SM, McMahon D, Abrams EJ, Bamji M, Purswani M, Engelson ES, et al. Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents. Pediatrics. 2009;123(1):e121.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Giacomet V, Vigano A, Manfredini V, Cerini C, Bedogni G, Mora S, et al. Cholecalciferol supplementation in HIV-infected youth with vitamin d insufficiency: effects on vitamin D status and T-cell phenotype: a randomized controlled trial. HIV Clin Trials. 2013;14(2):51–60.

    Article  CAS  PubMed  Google Scholar 

  117. Havens PL, Mulligan K, Hazra R, Flynn P, Rutledge B, Van Loan MD, et al. Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection. J Clin Endocrinol Metab. 2012;97(11):4004–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Cholongitas E, Theocharidou E, Goulis J, Tsochatzis E, Akriviadis E, Burroughs K. Review article: the extra-skeletal effects of vitamin D in chronic hepatitis C infection. Aliment Pharmacol Ther. 2012;35(6):634–46.

    Article  CAS  PubMed  Google Scholar 

  119. Clark PJ, Thompson AJ, Vock DM, Kratz LE, Tolun AA, Muir AJ, et al. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. Hepatology. 2012;56(1):49–56.

    Article  CAS  PubMed  Google Scholar 

  120. Masuda S, Okano T, Osawa K, Shinjo M, Suematsu T, Kobayashi T. Concentrations of vitamin D-binding protein and vitamin D metabolites in plasma of patients with liver cirrhosis. J Nutr Sci Vitaminol. 1989;35(4):225–34.

    Article  CAS  PubMed  Google Scholar 

  121. Gutierrez JA, Parikh N, Branch AD. Classical and emerging roles of vitamin D in hepatitis C virus infection. Semin Liver Dis. 2011;31(4):387–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. García-Álvarez M, Pineda-Tenor D, Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, Resino S. Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: a meta-analysis. Hepatology. 2014;60(5):1541–50.

    Article  PubMed  CAS  Google Scholar 

  123. Luo YQ, Wu XX, Ling ZX, Cheng YW, Yuan L, Xiang C. Association between serum vitamin D and severity of liver fibrosis in chronic hepatitis C patients: a systematic meta-analysis. J Zhejiang Univ Sci B. 2014;15(10):900–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Villar LM, Del Campo JA, Ranchal I, Lampe E, Romero-Gomez M. Association between vitamin D and hepatitis C virus infection: a meta-analysis. World J Gastroenterol. 2013;19(35):5917–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Kitson MT, Sarrazin C, Toniutto P, Eslick GD, Roberts SK. Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis. J Hepatol. 2014;61(6):1247–52.

    Article  CAS  PubMed  Google Scholar 

  126. Bitetto D, Fabris C, Fornasiere E, Pipan C, Fumolo E, Cussigh A, et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transpl Int. 2011;24(1):43–50.

    Article  CAS  PubMed  Google Scholar 

  127. Yokoyama S, Takahashi S, Kawakami Y, Hayes CN, Kohno H, Kohno H, et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. J Viral Hepat. 2014;21(5):348–56.

    Article  CAS  PubMed  Google Scholar 

  128. Esmat G, El Raziky M, Elsharkawy A, Sabry D, Hassany M, Ahmed A, et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. J Interferon Cytokine Res. 2015;35(1):49–54.

    Article  CAS  PubMed  Google Scholar 

  129. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina A-R, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World J Gastroenterol. 2011;17(47):5184–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Terrier B, Lapidus N, Pol S, Serfaty L, Ratziu V, Asselah T, et al. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. World J Gastroenterol. 2015;21(18):5647–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Atsukawa M, Tsubota A, Shimada N, Yoshizawa K, Abe H, Asano T, et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatol Res. 2016;46(5):450–8.

    Article  CAS  PubMed  Google Scholar 

  132. Nimer A, Mouch A, Vitamin D. improves viral response in hepatitis C genotype 2-3 naïve patients. World J Gastroenterol. 2012;18(8):800–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22(15):1979–91.

    Article  PubMed  Google Scholar 

  134. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33(4):562–9.

    Article  CAS  PubMed  Google Scholar 

  135. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New Engl J Med. 2004;351(5):438–50.

    Article  CAS  PubMed  Google Scholar 

  136. Amrein K. Vitamin D status in critical care: contributor or marker of poor health? Lung India. 2014;31(3):299–300.

    PubMed  PubMed Central  Google Scholar 

  137. Hewison M. Antibacterial effects of vitamin D. Nat Rev Endocrinol. 2011;7(6):337–45.

    Article  CAS  PubMed  Google Scholar 

  138. Davies PD, Martineau AR. Vitamin D and tuberculosis: more effective in prevention than treatment? Int J Tuberc Lung Dis. 2015;19(8):876–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Aarhus University Hospital, Aarhus N, Denmark

    Christian Wejse MD, PhD & Cecilie Blenstrup Patsche BSc

  2. Center for Global Health, Dept of Public Health, Aarhus University, Aarhus N, Denmark

    Christian Wejse MD, PhD & Cecilie Blenstrup Patsche BSc

Authors
  1. Christian Wejse MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cecilie Blenstrup Patsche BSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Wejse MD, PhD .

Editor information

Editors and Affiliations

  1. Lenox Hill Hospital, New York, New York, USA

    Emilia Pauline Liao

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Wejse, C., Patsche, C.B. (2018). Vitamin D and Infectious Diseases. In: Liao, E. (eds) Extraskeletal Effects of Vitamin D. Contemporary Endocrinology. Humana Press, Cham. https://doi.org/10.1007/978-3-319-73742-3_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-73742-3_3

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-73741-6

  • Online ISBN: 978-3-319-73742-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation